Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Armodafinil - Teva Pharmaceutical Industries

Drug Profile

Armodafinil - Teva Pharmaceutical Industries

Alternative Names: CEP-10953; Nuvigil; R-modafinil

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon
  • Developer Cephalon; Lindner Center of HOPE; Oncotherapeutics.; Teva Pharmaceutical Industries
  • Class Acetamides; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Biogenic amine receptor agonists; Catecholamine receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia
  • Phase III Eating disorders; Fatigue
  • Discontinued Bipolar depression; Schizophrenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypersomnia(In adolescents, In children) in Finland (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypersomnia(In adolescents, In children) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top